

Vienna, Austria

Annual Congress of the
European Association of Nuclear Medicine
October 21 –25, 2017
Vienna, Austria

**CME 12 (Translational Molecular Imaging and Therapy/Oncology/Neuroimaging)
Tuesday, October 24, 16:30-18.00**

Session Title

18F-DOPA and Radiolabelled Choline PET in Recurrent Glioblastoma

Chairs

Egesta Lopci (Milan)

Ian Law (Copenhagen)

Programme

- 16:30 - 17:00 Giuseppe Lombardi (Padova): The Need of Oncologists: Can Imaging Satisfy them?
- 17:00 - 17.30 Karen Salzman (Salt Lake City): Advanced Imaging with MRI: Impact of DCE/DSC and DWI on the Diagnosis or Relapsed Gliomas
- 17:30 - 18:00 Jacques Darcourt (Nice): Potential Role of F-DOPA and Choline PET in Recurrent Glioblastoma

Educational Objectives

At the end of this educational session, the participants will be able to define the differential diagnosis between recurrence of glioblastoma and pseudoprogression, by using functional (MRI) and metabolic (18F-DOPA or radiolabeled choline PET/CT or PET/MRI) imaging modalities.

Summary

The aim of the present session is to illustrate the utility of functional and metabolic imaging in detecting the recurrence of disease in patients with glioblastomas. Usually, after surgical and radiation therapy approaches, the morphological characteristics of brain are completely changed and therefore the differential diagnosis between recurrent disease and pseudoprogression is difficult to assess. In this session, we will present and discuss complementary information provided by MRI, PET/CT and PET/MRI with metabolic radiopharmaceutical agents (18F-DOPA and Choline) and their role for the identification of recurrent glioblastoma.

Key Words

Glioblastoma; MRI; PET/CT; PET/MRI; 18F-DOPA; radiolabeled Choline